## COVID-19 KNOWLEDGE SUMMARY: 22<sup>nd</sup> May 2020



To keep up to date with the latest reports, guidelines and news, see the Library and Knowledge Service's Knowledge Pages at: http://www.knowledge-nw.nhs.uk/knowledge/Pages/RSSPage.aspx



## NICE: Medtech innovation briefing [MIB217] Cytokine adsorption devices for treating respiratory failure in people with COVID-19

https://www.nice.org.uk/advice/mib217

- The technologies described in this briefing are cytokine adsorption devices. They are for • reducing blood levels of cytokines in people with COVID-19 and respiratory failure.
- The innovative aspects are that the cytokine adsorption devices reduce harmful levels of • cytokines in the blood.
- The intended place in therapy would be in addition to critical care for people with COVID-19 and respiratory failure.
- The main points from the evidence summarised in this briefing are from a non-randomised • comparative single-arm observational study and a series of case reports including 56 patients with COVID-19 and respiratory failure. It shows that cytokine adsorption devices reduce levels of cytokines in the blood in people with COVID-19. This may help improve lung function.
- Key uncertainties around the evidence or technology are that most of the evidence is from company websites and is not peer reviewed. The clinical experience of using cytokine adsorbent devices in people with COVID-19 is reported as low-quality evidence, such as case reports with small sample sizes. None of these were done in the NHS.
- Safety issues identified are a safety notice advising that CytoSorb should not be used with nitrous oxide. Also, there is a Medical Device Alert for the Spectra Optia Apheresis System because of a risk of improper use if company instructions are not followed carefully.
- The cost of the cytokine adsorption cartridges ranges from £450 to £1,785 per unit • (excluding VAT). The cost of machines using extracorporeal circuits ranges from £10,000 up to £60,000 and are already available in NHS hospitals, but some machines are only available in specialist centres. The resource impact would be greater than standard care because the technology is intended to be used in addition to standard care.



### ECDC: Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children

https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystemsyndrome-and-sars-cov-2-rapid-risk-assessment

Several countries affected by the coronavirus disease (COVID-19) pandemic recently reported cases of children that were hospitalised in intensive care due to a rare paediatric inflammatory multisystem syndrome (PIMS). The presenting signs and symptoms are a mix of the ones for Kawasaki disease (KD) and toxic shock syndrome (TSS) and are characterised, among others, by fever, abdominal pain and cardiac involvement. A possible temporal association with SARS-COV-2 infection has been hypothesised because some of the children that were tested for SARS-CoV-2 infection were either positive by polymerase chain reaction (PCR) or serology.



XO3

**Public Health** 

England

**British Association of Stroke Physicians: Adapting stroke services during the COVID-19 pandemic: an implementation guide** <u>https://basp.ac.uk/adapting-</u> <u>stroke-services-during-the-covid-19-pandemic-an-implementation-guide/resource-hub/</u> The Getting It Right First Time (GIRFT) programme and the Oxford Academic Health Science Network (AHSN) have collaborated to produce guidance for adapting stroke services during the COVID-19 pandemic – and reshaping them afterwards.

### **Public Health England Guidance**

UPDATED: COVID-19: guidance for stepdown of infection control precautions within hospitals and discharging COVID-19 patients from hospital to home settings https://www.gov.uk/government/publications/covid-19-guidance-for-stepdown-of-infectioncontrol-precautions-within-hospitals-and-discharging-covid-19-patients-from-hospital-tohome-settings

Advice on appropriate infection prevention and control (IPC) precautions for stepdown in hospital or discharge to home or residential settings. Updated 20<sup>th</sup> May 2020

# UPDATED: COVID-19: management of exposed staff and patients in health and social care settings

https://www.gov.uk/government/publications/covid-19-management-of-exposed-healthcareworkers-and-patients-in-hospital-settings

Guidance on the management of staff and patients who have been exposed to COVID-19. Updated 20<sup>th</sup> May 2020

#### UPDATED: COVID-19: infection prevention and control (IPC)

https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infectionprevention-and-control

Guidance on infection prevention and control for COVID-19. Sustained community transmission is occurring across the UK. Updated 20<sup>th</sup> May 2020

# UPDATED: COVID-19: guidance on shielding and protecting people defined on medical grounds as extremely vulnerable

https://www.gov.uk/government/publications/guidance-on-shielding-and-protectingextremely-vulnerable-persons-from-covid-19

Information for shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19. Updated 18<sup>th</sup> May 2020

UPDATED: COVID-19: investigation and initial clinical management of possible cases

https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigationof-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhannovel-coronavirus-wn-cov-infection#criteria

Updated case definition in section 2 with addition of a loss of, or change in, normal sense of taste or smell (anosmia). Updated 18<sup>th</sup> May 2020

#### Library & Knowledge Service

St Helens & Knowsley Teaching Hospitals NHS Trust, Nightingale House, Whiston Hospital email: <u>library@sthk.nhs.uk</u> tel: 0151 430 1342 website: <u>http://www.knowledge-nw.nhs.uk/Pages/home.aspx</u>